Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
20 hedge funds and large institutions have $558K invested in Iterum Therapeutics in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 7 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0.29% more ownership
Funds ownership: 2.87% → 3.16% (+0.29%)
17% less funds holding
Funds holding: 24 → 20 (-4)
38% less capital invested
Capital invested by funds: $904K → $558K (-$346K)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AF
Apollon Financial
Mount Pleasant,
South Carolina
|
+$205K |
| 2 |
Jane Street
New York
|
+$148K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$60K |
| 4 |
CAPTRUST Financial Advisors
Raleigh,
North Carolina
|
+$14.6K |
| 5 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Squarepoint
New York
|
-$297K |
| 2 |
OIA
OneDigital Investment Advisors
Overland Park,
Kansas
|
-$128K |
| 3 |
Renaissance Technologies
New York
|
-$54.7K |
| 4 |
VF
Virtu Financial
New York
|
-$13.5K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7.84K |
ITRM Hedge Fund Activity: Q4 2025 in Review
20 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q4 2025, worth a combined $558K — down 38% from $904K a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ITRM and 3 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 5 added.
The largest buyer was Apollon Financial, adding an estimated $205K. The largest seller was Squarepoint, exiting entirely with an estimated $297K sold.
- 20 institutional investors held Iterum Therapeutics (ITRM) as of Q4 2025, down from 24 in Q3 2025.
- Funds reported $558K of Iterum Therapeutics stock for Q4 2025, down 38% quarter-over-quarter.
- 3 funds opened new Iterum Therapeutics positions in Q4 2025 and 7 closed out, a net change of -4 holders.
- The largest Iterum Therapeutics buyer in Q4 2025 was Apollon Financial, an estimated $205K added.
- The largest Iterum Therapeutics seller in Q4 2025 was Squarepoint, an estimated $297K sold.
Based on aggregated 13F filings for Q4 2025.